aHelsinki Institute for Life Science (HiLIFE) and Faculty of Medicine, Biochemistry and Developmental Biology, Meilahti Clinical Proteomics Core Facility
bHelsinki Normal Lyceum, Faculty of Educational Sciences, University of Helsinki; Helsinki
cDepartment of Pathology, HUSLAB and Helsinki University Hospital, Helsinki and Espoo
dDepartments of Pathology and Pulmonary Diseases, Lapland Central Hospital, Rovaniemi
eFinnish Institute of Occupational Health (FIOH)
fFinnish Institute for Verification of the Chemical Weapons Convention (VERIFIN), Department of Chemistry, University of Helsinki, Helsinki, Finland
Received 1 February 2019 Accepted 11 July 2019
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.eurjcancerprev.com).
Correspondence to Marc Baumann, MSc, Helsinki Institute for Life Science (HiLIFE) and Faculty of Medicine, Biochemistry and Developmental Biology, Meilahti Clinical Proteomics Core Facility, University of Helsinki, Helsinki, Finland, Tel: +358505671980; e-mail: [email protected]